Immune checkpoint inhibitor therapy: a major breakthrough in treating triple-negative breast cancer

Triple-negative breast cancer (TNBC) is an aggressive and challenging subtype of breast cancer characterized by poor prognosis and limited treatment options. Conventional therapies, primarily based on chemotherapy, often prove ineffective and are associated with significant side effects. Against this backdrop, the emergence of immune checkpoint inhibitors (ICI), such as PD-1/PD-L1 inhibitors, has opened new avenues for treatment. These therapies stimulate the immune system to recognize and destroy cancer cells and are generating growing interest. However, their precise role in the management of TNBC remains to be fully elucidated. This study evaluates the efficacy and safety of ICIs in treating unresectable, locally advanced, or…